EV/FCF Ratio: 41.63x
Is the EV/FCF ratio high or low?
The EV/FCF ratio of 41.63x is 17% below its 5-year average of 50.25x, near the low end of its 5-year range (25.51x–89.67x).
As of Saturday, June 27, 2026. 5.54% above its 12-month average of 39.44x.
TECH EV/FCF Ratio Chart
TECH Average EV/FCF Ratio Chart
TECH Current vs Average EV/FCF Ratio Chart
TECH EV/FCF Ratio Metrics
EV/FCF RATIO
41.63x
EV/FCF RATIO AVG TTM
39.44x
EV/FCF RATIO AVG 3Y
45.92x
EV/FCF RATIO AVG 5Y
49.05x
EV/FCF RATIO AVG 10Y
48.79x
EV/FCF RATIO AVG 15Y
41.51x
EV/FCF RATIO AVG 20Y
37.18x
CURRENT VS TTM AVG
+5.54%
CURRENT VS 3Y AVG
-9.34%
CURRENT VS 5Y AVG
-15.13%
CURRENT VS 10Y AVG
-14.68%
CURRENT VS 15Y AVG
+0.29%
CURRENT VS 20Y AVG
+11.98%
TECH Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 41.63x | 39.44x | 45.92x | 49.05x |
| Insulet Corp. (PODD)vs › | $10.96B | 28.09x | 50.55x | 77.08x | 77.08x |
| Baxter International Inc. (BAX)vs › | $11.38B | 26.64x | 63.98x | 51.38x | 47.25x |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | 38.45x | 25.13x | 44.16x | 28.93x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 66.60x | 67.40x | 78.57x | 42.55x |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.20B | 33.93x | 21.74x | 28.87x | 35.14x |
| Tempus AI, Inc. (TEM)vs › | $9.80B | N/A | N/A | N/A | N/A |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 31.25x | 28.87x | 26.66x | 23.98x |
| Revvity, Inc. (RVTY)vs › | $12.61B | 30.64x | 26.85x | 265.07x | 164.29x |
| Align Technology, Inc. (ALGN)vs › | $12.78B | 16.96x | 17.60x | 29.15x | 38.56x |
Cash Flow Valuation Comparison
EV/FCF
41.6x
P/FCF
41.3x
FCF Yield
2.42%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Bio-Techne Corporation (TECH)?
- The EV/FCF ratio for TECH stock is 41.63x.
- Is Bio-Techne Corporation's EV/FCF ratio high or low?
- The EV/FCF ratio of 41.63x is 17% below its 5-year average of 50.25x, near the low end of its 5-year range (25.51x–89.67x).
- What is the TTM average EV/FCF ratio for Bio-Techne Corporation (TECH)?
- The TTM average EV/FCF ratio for TECH stock is 39.44x.
- What is the 3Y average EV/FCF ratio for Bio-Techne Corporation (TECH)?
- The 3Y average EV/FCF ratio for TECH stock is 45.92x.
- What is the 5Y average EV/FCF ratio for Bio-Techne Corporation (TECH)?
- The 5Y average EV/FCF ratio for TECH stock is 49.05x.
- What is the 10Y average EV/FCF ratio for Bio-Techne Corporation (TECH)?
- The 10Y average EV/FCF ratio for TECH stock is 48.79x.
- What is the 15Y average EV/FCF ratio for Bio-Techne Corporation (TECH)?
- The 15Y average EV/FCF ratio for TECH stock is 41.51x.
- What is the 20Y average EV/FCF ratio for Bio-Techne Corporation (TECH)?
- The 20Y average EV/FCF ratio for TECH stock is 37.18x.
TECH EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-26 | 41.63x |
| 2026-06-25 | 41.46x |
| 2026-06-24 | 34.57x |
| 2026-06-23 | 33.05x |
| 2026-06-22 | 32.67x |
| 2026-06-18 | 34.03x |
| 2026-06-17 | 32.32x |
| 2026-06-16 | 32.92x |
| 2026-06-15 | 33.00x |
| 2026-06-12 | 31.73x |
| 2026-06-11 | 31.75x |
| 2026-06-10 | 30.86x |
| 2026-06-09 | 31.97x |
| 2026-06-08 | 30.95x |
| 2026-06-05 | 30.56x |
| 2026-06-04 | 31.26x |
| 2026-06-03 | 29.90x |
| 2026-06-02 | 29.27x |
| 2026-06-01 | 29.87x |
| 2026-05-29 | 30.38x |
| 2026-05-28 | 29.89x |
| 2026-05-27 | 28.29x |
| 2026-05-26 | 28.22x |
| 2026-05-22 | 28.36x |
| 2026-05-21 | 27.87x |
| 2026-05-20 | 27.48x |
| 2026-05-19 | 26.77x |
| 2026-05-18 | 26.16x |
| 2026-05-15 | 25.51x |
| 2026-05-14 | 26.34x |
| 2026-05-13 | 26.43x |
| 2026-05-12 | 27.90x |
| 2026-05-11 | 27.90x |
| 2026-05-08 | 28.45x |
| 2026-05-07 | 29.94x |
| 2026-05-06 | 27.90x |
| 2026-05-05 | 40.70x |
| 2026-05-04 | 39.33x |
| 2026-05-01 | 39.53x |
| 2026-04-30 | 39.74x |
| 2026-04-29 | 37.37x |
| 2026-04-28 | 38.47x |
| 2026-04-27 | 39.59x |
| 2026-04-24 | 38.95x |
| 2026-04-23 | 37.55x |
| 2026-04-22 | 42.04x |
| 2026-04-21 | 42.80x |
| 2026-04-20 | 43.44x |
| 2026-04-17 | 42.49x |
| 2026-04-16 | 41.18x |
| 2026-04-15 | 41.97x |
| 2026-04-14 | 42.09x |
| 2026-04-13 | 41.30x |
| 2026-04-10 | 39.90x |
| 2026-04-09 | 39.92x |
| 2026-04-08 | 39.66x |
| 2026-04-07 | 38.69x |
| 2026-04-06 | 38.67x |
| 2026-04-02 | 38.20x |
| 2026-04-01 | 38.45x |
| 2026-03-31 | 37.59x |
| 2026-03-30 | 37.43x |
| 2026-03-27 | 36.67x |
| 2026-03-26 | 37.90x |
| 2026-03-25 | 37.89x |
| 2026-03-24 | 37.71x |
| 2026-03-23 | 37.40x |
| 2026-03-20 | 37.04x |
| 2026-03-19 | 37.12x |
| 2026-03-18 | 36.57x |
| 2026-03-17 | 36.74x |
| 2026-03-16 | 35.16x |
| 2026-03-13 | 36.59x |
| 2026-03-12 | 37.03x |
| 2026-03-11 | 38.54x |
| 2026-03-10 | 37.98x |
| 2026-03-09 | 39.42x |
| 2026-03-06 | 38.74x |
| 2026-03-05 | 40.14x |
| 2026-03-04 | 41.52x |
| 2026-03-03 | 40.92x |
| 2026-03-02 | 41.50x |
| 2026-02-27 | 42.33x |
| 2026-02-26 | 41.57x |
| 2026-02-25 | 41.54x |
| 2026-02-24 | 41.35x |
| 2026-02-23 | 39.35x |
| 2026-02-20 | 41.29x |
| 2026-02-19 | 41.80x |
| 2026-02-18 | 42.56x |
| 2026-02-17 | 41.98x |
| 2026-02-13 | 42.99x |
| 2026-02-12 | 42.71x |
| 2026-02-11 | 45.46x |
| 2026-02-10 | 46.42x |
| 2026-02-09 | 46.89x |
| 2026-02-06 | 47.81x |
| 2026-02-05 | 47.16x |
| 2026-02-04 | 49.14x |
| 2026-02-03 | 46.22x |
| 2026-02-02 | 46.65x |
| 2026-01-30 | 45.84x |
| 2026-01-29 | 45.76x |
| 2026-01-28 | 46.87x |
| 2026-01-27 | 48.73x |
| 2026-01-26 | 48.31x |
| 2026-01-23 | 48.68x |
| 2026-01-22 | 49.72x |
| 2026-01-21 | 50.93x |
| 2026-01-20 | 49.66x |
| 2026-01-16 | 49.04x |
| 2026-01-15 | 49.94x |
| 2026-01-14 | 48.85x |
| 2026-01-13 | 47.42x |
| 2026-01-12 | 47.56x |
| 2026-01-09 | 46.96x |
| 2026-01-08 | 46.18x |
| 2026-01-07 | 46.51x |
| 2026-01-06 | 46.67x |
| 2026-01-05 | 45.10x |
| 2026-01-02 | 42.74x |
| 2025-12-31 | 42.16x |
| 2025-12-30 | 42.37x |
| 2025-12-29 | 42.46x |
| 2025-12-26 | 42.44x |
| 2025-12-24 | 42.42x |
| 2025-12-23 | 42.46x |
| 2025-12-22 | 42.26x |
| 2025-12-19 | 41.78x |
| 2025-12-18 | 40.96x |
| 2025-12-17 | 40.89x |
| 2025-12-16 | 41.20x |
| 2025-12-15 | 42.07x |
| 2025-12-12 | 41.95x |
| 2025-12-11 | 43.17x |
| 2025-12-10 | 43.57x |
| 2025-12-09 | 42.16x |
| 2025-12-08 | 43.19x |
| 2025-12-05 | 44.16x |
| 2025-12-04 | 45.46x |
| 2025-12-03 | 45.65x |
| 2025-12-02 | 45.04x |
| 2025-12-01 | 45.61x |
| 2025-11-28 | 46.13x |
| 2025-11-26 | 46.22x |
| 2025-11-25 | 47.07x |
| 2025-11-24 | 45.42x |
| 2025-11-21 | 44.05x |
| 2025-11-20 | 42.10x |
| 2025-11-19 | 41.46x |
| 2025-11-18 | 41.69x |
| 2025-11-17 | 42.02x |
| 2025-11-14 | 42.55x |
| 2025-11-13 | 43.51x |
| 2025-11-12 | 43.96x |
| 2025-11-11 | 42.41x |
| 2025-11-10 | 41.21x |
| 2025-11-07 | 41.18x |
| 2025-11-06 | 41.72x |
| 2025-11-05 | 42.94x |
| 2025-11-04 | 38.19x |
| 2025-11-03 | 38.29x |
| 2025-10-31 | 39.09x |
| 2025-10-30 | 38.11x |
| 2025-10-29 | 38.75x |
| 2025-10-28 | 39.92x |
| 2025-10-27 | 40.11x |
| 2025-10-24 | 41.11x |
| 2025-10-23 | 41.21x |
| 2025-10-22 | 39.83x |
| 2025-10-21 | 39.63x |
| 2025-10-20 | 39.07x |
| 2025-10-17 | 38.66x |
| 2025-10-16 | 38.50x |
| 2025-10-15 | 37.27x |
| 2025-10-14 | 37.08x |
| 2025-10-13 | 37.31x |
| 2025-10-10 | 36.71x |
| 2025-10-09 | 37.47x |
| 2025-10-08 | 37.87x |
| 2025-10-07 | 37.03x |
| 2025-10-06 | 38.69x |
| 2025-10-03 | 39.32x |
| 2025-10-02 | 38.79x |
| 2025-10-01 | 37.48x |
| 2025-09-30 | 34.87x |
| 2025-09-29 | 32.81x |
| 2025-09-26 | 32.58x |
| 2025-09-25 | 31.75x |
| 2025-09-24 | 32.20x |
| 2025-09-23 | 33.23x |
| 2025-09-22 | 33.30x |
| 2025-09-19 | 33.37x |
| 2025-09-18 | 33.27x |
| 2025-09-17 | 32.38x |
| 2025-09-16 | 32.54x |
| 2025-09-15 | 32.44x |
| 2025-09-12 | 32.22x |
| 2025-09-11 | 33.40x |
| 2025-09-10 | 32.04x |
| 2025-09-09 | 34.00x |
| 2025-09-08 | 33.95x |
| 2025-09-05 | 34.13x |
| 2025-09-04 | 33.23x |
| 2025-09-03 | 33.48x |
| 2025-09-02 | 33.53x |
| 2025-08-29 | 34.27x |
| 2025-08-28 | 34.08x |
| 2025-08-27 | 35.23x |
| 2025-08-26 | 35.58x |
| 2025-08-25 | 35.53x |
| 2025-08-22 | 35.76x |
| 2025-08-21 | 40.16x |
| 2025-08-20 | 40.40x |
| 2025-08-19 | 40.79x |
| 2025-08-18 | 39.65x |
| 2025-08-15 | 39.87x |
| 2025-08-14 | 39.97x |
| 2025-08-13 | 40.67x |
| 2025-08-12 | 39.32x |
| 2025-08-11 | 37.39x |
| 2025-08-08 | 37.58x |
| 2025-08-07 | 37.39x |
| 2025-08-06 | 37.19x |
| 2025-08-05 | 40.62x |
| 2025-08-04 | 40.79x |
| 2025-08-01 | 40.80x |
| 2025-07-31 | 40.69x |
| 2025-07-30 | 42.83x |
| 2025-07-29 | 42.95x |
| 2025-07-28 | 43.44x |
| 2025-07-25 | 43.60x |
| 2025-07-24 | 43.38x |
| 2025-07-23 | 41.10x |
| 2025-07-22 | 39.53x |
| 2025-07-21 | 37.48x |
| 2025-07-18 | 38.74x |
| 2025-07-17 | 39.65x |
| 2025-07-16 | 38.57x |
| 2025-07-15 | 38.30x |
| 2025-07-14 | 39.17x |
| 2025-07-11 | 40.26x |
| 2025-07-10 | 40.46x |
| 2025-07-09 | 39.15x |
| 2025-07-08 | 39.21x |
| 2025-07-07 | 38.39x |
| 2025-07-03 | 39.54x |
| 2025-07-02 | 39.57x |
| 2025-07-01 | 38.78x |
| 2025-06-30 | 38.33x |
| 2025-06-27 | 38.61x |
| 2025-06-26 | 39.30x |
| 2025-06-25 | 38.64x |
| 2025-06-24 | 37.28x |
| 2025-06-23 | 36.78x |
| 2025-06-20 | 37.20x |
| 2025-06-18 | 37.37x |
| 2025-06-17 | 36.92x |
| 2025-06-16 | 38.45x |
| 2025-06-13 | 37.66x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman